Clinical trials: Infection and Inflammatory Reaction
Sepsis, Coagulopathy
A Study to Learn About How Safe BAY 3389934 is, Its Suitable Dose, and How it Affects the Participants With Sepsis Induced Coagulopathy
Researchers are looking for a better way to treat people who have sepsis induced coagulopathy. Sepsis happens when bacteria and their toxins spread in the blood, causing an infection.
- Trial name
- NCT06854640
- Testing
- BAY3389934
- Where
- 21 sites in United States, Belgium and 3 more
- Volunteers
- 36 people
- Sponsor
- Bayer
Sepsis
Efficacy & Safety of Resatorvid in Adults With Severe Sepsis
The purpose of this study is to determine the optimal dose of Resatorvid for reducing 28-day all-cause mortality in subjects with severe sepsis.
- Trial name
- NCT00143611
- Testing
- Resatorvid
- Where
- 144 sites in United States, Australia and 15 more
- Volunteers
- 277 people
- Sponsor
- Takeda
Sepsis
Pharmacoeconomic Analysis of First Line Meropenem Versus Standard Antibiotic Treatment in Seriously Infected Secondary Nosocomial Sepsis Syndrome Patients.
This study will directly compare meropenem with standard first line antibiotic therapies in subjects entering an ICU with secondary nosocomial sepsis, or who contract sepsis while resident in an ICU.
- Trial name
- NCT00318552
- Testing
- Meropenem
- Where
- 12 sites in Hungary
- Volunteers
- 160 people
- Sponsor
- Pfizer
Bacterial Infections
Zithromax-SR 2g, Special Investigation (Regulatory Post Marketing Commitment Plan)
To collect the efficacy and safety information of Zithromax-SR related to their appropriate use in daily practice.
- Trial name
- NCT00998309
- Testing
- Azithromycin SR
- Volunteers
- 502 people
- Sponsor
- Pfizer
Infectious Skin Diseases, Bacterial Skin Diseases
Safety and Efficacy Study of Oxazolidinones to Treat Uncomplicated Skin Infections
The purpose of this study is to assess the efficacy, safety and tolerability of RX-1741, an oxazolidinone, versus linezolid, another oxazolidinone, in the treatment of uncomplicated skin and skin structure infections
- Conditions
- Infectious Skin Diseases, Bacterial Skin Diseases, Staphylococcal Skin Infections, Streptococcal Infections
- Trial name
- NCT00646958
- Testing
- Radezolid, Linezolid
- Where
- 19 sites in United States
- Volunteers
- 150 people
- Sponsor
- Melinta Therapeutics, Inc.
Toxic Shock Syndrome, Vaccination; Sepsis
rTSST-1 Variant Vaccine Phase 1 First-in-man Trail
Toxic Shock Syndrome (TSS) a severe condition with high morbidity and mortality results from the hosts overwhelming inflammatory response and cytokine storm. Staphylococcal superantigen toxins are the main causative agents.
- Trial name
- rTSST-1 (NCT02340338)
- Testing
- rTSST-1 Variant Candidate Vaccine
- Where
- Austria
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- Biomedizinische Forschungs gmbH
Complicated Skin and Soft Tissue Infection
Evaluation of Ceftaroline Fosamil vs Vancomycin Plus Aztreonam in the Treatment of Patients With Skin Infections.
The purpose of this study is to evaluate the effects of Ceftaroline Fosamil versus Vancomycin plus Aztreonam in treatment of patients with complicated bacterial skin and soft tissue infections.
- Trial name
- NCT02202135
- Testing
- Ceftaroline fosamil, Vancomycin, Aztreonam
- Where
- 22 sites in Argentina, Brazil and 11 more
- Volunteers
- 4 people
- Sponsor
- Pfizer
Septic Shock
Early Albumin Resuscitation During Septic Shock
Objective: To determine whether the early administration of albumin as an expander and antioxidant would improve survival on the 28th day for septic shock patients.
- Trial name
- NCT00327704
- Testing
- albumin, saline
- Where
- France
- Volunteers
- 794 people
- Sponsor
- Laboratoire français de Fractionnement et de Biotechnologies
Bacteremia, Staphylococcus Aureus
Study Evaluating Safety, Tolerability, and Efficacy of Intravenous AP-SA02 in Subjects With S. Aureus Bacteremia
Phase 1b/2a, Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Escalation Study of the Safety, Tolerability, and Efficacy of Intravenous AP SA02 as an Adjunct to Best Available Antibiotic Therapy Compared to…
- Conditions
- Bacteremia, Staphylococcus Aureus, Staphylococcus Aureus Bacteremia, Bacteremia Staph
- Trial name
- diSArm (NCT05184764)
- Testing
- AP-SA02
- Where
- 28 sites in United States, Australia
- Volunteers
- 56 people
- Sponsor
- Armata Pharmaceuticals, Inc.
Bacteremia, Soft Tissue Infections
Safety, Efficacy, and Pharmacokinetics (PK) of Daptomycin (MK-3009) in Japanese Pediatric Subjects With Complicated Skin and Soft Tissue Infections (cSSTI) and Bacteremia (MK-3009-029)
The purpose of this study is to assess the safety, efficacy and pharmacokinetic (PK) parameters of daptomycin for injection in Japanese pediatric participants aged 1 to 17 years with complicated skin and soft tissue infection…
- Conditions
- Bacteremia, Soft Tissue Infections, Skin Diseases, Infectious
- Trial name
- NCT03643952
- Testing
- Daptomycin for Injection
- Where
- 16 sites in Japan
- Volunteers
- 18 people
- Sponsor
- Merck Sharp & Dohme LLC
Complications; Catheter, Urinary Infection or Inflammation
BIP Foley in Prevention of CAUTI at Rehab Station
This is a prospective, cross-over, randomized, controlled, partly blinded study evaluating safety and performance of noble metal alloy urinary Catheters (BIP Foley, Bactiguard AB) of both latex and silicone.
- Trial name
- CDOC (NCT02808000)
- Testing
- BIP Foley (latex) or BIP Foley -silicone, Standard catheter
- Where
- Sweden
- Volunteers
- 14 people
- Sponsor
- Bactiguard AB
Bacteremia
A Phase 3 Telavancin Staphylococcus Aureus (S. Aureus) Bacteremia Trial
This is a multicenter, randomized, open-label, noninferiority trial of telavancin versus standard IV therapy control (e.g., vancomycin, daptomycin, anti-staphylococcal penicillin (PCN), or cefazolin) in the treatment of subjects…
- Trial name
- NCT02208063
- Testing
- Telavancin, Vancomycin, Daptomycin
- Where
- United States
- Volunteers
- 121 people
- Sponsor
- Cumberland Pharmaceuticals
Abscess, Wound Infection
Single Dose vs. Two Dose Regimen of Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections
To compare the efficacy of treatment with a single dose of dalbavancin 1500 mg to treatment with a two dose regimen of dalbavancin (1000 mg on Day 1 followed by 500 mg on Day 8) in participants with known or suspected…
- Conditions
- Abscess, Wound Infection, Surgical Site Infection, Cellulitis
- Trial name
- NCT02127970
- Testing
- Dalbavancin
- Where
- 78 sites in United States, Bulgaria and 10 more
- Volunteers
- 698 people
- Sponsor
- Durata Therapeutics Inc., an affiliate of Allergan plc
Covid19, COVID-19 Lower Respiratory Infection
In-patient COVID-19 Study of Intranasal Foralumab
This is a Phase 2, randomized, placebo-controlled, double-blind, proof-of-concept study of intranasal foralumab in hospitalized subjects with severe COVID-19 and pulmonary inflammation.
- Conditions
- Covid19, COVID-19 Lower Respiratory Infection, COVID-19 Respiratory Infection
- Trial name
- NCT04983446
- Testing
- Foralumab
- Sponsor
- Tiziana Life Sciences LTD
Sepsis
Clinical Trial to Evaluate MDW for Early Detection of Sepsis
This study is intended to clinically verify Monocyte Distribution Width (MDW) parameter of DxH 900 Hematology Analyzer for use in early detection and risk assessment of sepsis, severe sepsis, and septic shock in critically ill…
- Trial name
- NCT06267742
- Testing
- Complete Blood Count (CBC) with Differential
- Where
- 3 sites in China
- Volunteers
- 2,200 people
- Sponsor
- Beckman Coulter, Inc.
Hematological Malignancy, Hematopoetic Stem Cell Transplantation
Middle East Study of Infections in Patients With Hematological Malignancies
The goal of this prospective observational study is to is to prospectively study the epidemiology of bloodstream infection (BSI) in patients with hematological malignancies (HM) and hematopoietic stem cell transplant (HSCT)…
- Conditions
- Hematological Malignancy, Hematopoetic Stem Cell Transplantation, Bloodstream Infection
- Trial name
- MESI-HM (NCT07900542)
- Testing
- No Intervention: Observational Cohort
- Where
- 9 sites in Jordan, Oman and 3 more
- Volunteers
- 1,000 people
- Sponsor
- Hamad Medical Corporation
Sepsis
Discharge Readmission Analysis and Management in Sepsis (DReAMS-2)
This is an adaptive platform. This study is being done to collect information that will help us identify trends in patients with sepsis and other health conditions being readmitted into hospitals within 30 days of being…
- Trial name
- NCT06099756
- Where
- 3 sites in United States
- Volunteers
- 2,000 people
- Sponsor
- Measure Labs, Inc.
Osteoarthritis, Arthritis
Bipolar Sealer Aquamantys Use in Total Knee Replacement
This study will compare the clinical outcomes for patients undergoing a total knee replacement using a bipolar sealer, the Aquamantys® System, as compared to standard electrocautery.
- Conditions
- Osteoarthritis, Arthritis, Surgery, Infection
- Trial name
- NCT01736644
- Testing
- Electrocautery, Bipolar sealer Aquamantys
- Where
- 2 sites in United Kingdom
- Volunteers
- 97 people
- Sponsor
- Medtronic Surgical Technologies
Healthy Subjects (Indication: Asthma)
A Study to Investigate the Safety, Tolerability and Pharmacokinetics of Elarekibep in Healthy Japanese Subjects
This study will assess the safety, tolerability and pharmacokinetics (PK) of elarekibep after single and multiple doses given twice daily (BID) by inhalation or intravenous (IV) in healthy Japanese subjects compared with placebo.
- Trial name
- NCT05794672
- Testing
- Elarekibep
- Where
- United Kingdom
- Volunteers
- 30 people
- Sponsor
- AstraZeneca
Candidemia, Mycoses
CD101 Compared to Caspofungin Followed by Oral Step Down in Subjects With Candidemia and/or Invasive Candidiasis-Bridging Extension
The purpose of this study is to determine if intravenous CD101 is safe and effective in the treatment of candidemia and/or invasive candidiasis when compared to caspofungin (followed by oral fluconazole).
- Conditions
- Candidemia, Mycoses, Fungal Infection, Fungemia
- Trial name
- STRIVE (NCT02734862)
- Testing
- CD101, Caspofungin, Fluconazole
- Where
- 63 sites in United States, Belgium and 8 more
- Volunteers
- 207 people
- Sponsor
- Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)